share_log

Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September

Defense World ·  Sep 30, 2022 14:11

Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.

Advaxis Stock Up 2.3 %

ADXS opened at $2.21 on Friday. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The firm has a market cap of $4.00 million, a price-to-earnings ratio of -22.05 and a beta of 2.07. The stock has a 50-day simple moving average of $3.23.

Get Advaxis alerts:

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.

About Advaxis

(Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • Humana Proves Vertically Integrated Healthcare Works
  • What Cintas Can Teach Investors About This Bear Market?
  • 2 Casino Stocks Worth Taking a Look At
  • This Small-Cap Healthcare Name Is Outperforming Its Index
  • Blackberry Stock Declines As Results Come In Lukewarm Once Again

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment